Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.

UPDATE: Biosimilars to Humira to Launch in January 2023

Beginning next month and continuing throughout 2023, it is expected that 14 or more biosimilar versions of AbbVie’s Humira (adalimumab) will be launched to market, marking the largest loss-of-exclusivity event in the history of pharmaceuticals. As of December 13, 2022, eight biosimilars have been approved by the Food and Drug Administration. Although pricing information will likely not be available until closer to each product’s launch date, we expect that some biosimilars for Humira will be placed on ProAct’s preferred brand drug list.

UPDATE: Biosimilars to Humira to Launch in January 2023 hero image
DRUG MANUFACTURER DATE APPROVED EXPECTED LAUNCH DATE

Amjevita

Amgen

09/23/2016

01/31/2023

Abrilada

Pfizer

11/15/2019

07/01/2023

Cyltezo

Boehringer Ingelheim

08/25/2017

07/01/2023

Hadlima

Samsung Bioepis/Organon

07/23/2019

07/01/2023

Idacio Fresenius Kabi 12/13/2022 07/01/2023

Yusimry

Coherus

12/17/2021

07/01/2023

Hulio

Viatris/Biocon

07/06/2020

As early as 07/2023

Hyrimoz

Novartis

10/30/2018

As early as 07/2023

 

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image